US20050282774A1 - Method and pharmaceutical to treat spinal discs - Google Patents
Method and pharmaceutical to treat spinal discs Download PDFInfo
- Publication number
- US20050282774A1 US20050282774A1 US11/210,307 US21030705A US2005282774A1 US 20050282774 A1 US20050282774 A1 US 20050282774A1 US 21030705 A US21030705 A US 21030705A US 2005282774 A1 US2005282774 A1 US 2005282774A1
- Authority
- US
- United States
- Prior art keywords
- disc
- stock solution
- injectable
- disrupted
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Definitions
- An injectable for, and a method of use to treat spinal discs is provided.
- the human skeleton has evolved to allow for upright posture and bipedal motion.
- the human spine in its development to support the upright body has developed areas of stress particularly at the base of the neck, the apex of the mid back (thoracic spine) and in the lower back (lower lumbar spine).
- the spine is formed by bony elements, the vertebrae, and cushions between vertebrae, the intervertebral discs.
- the spine is then supported by ligaments, fibrous bands of tissue that join bones together, and muscles and fascia, which provide dynamic support and zygapophyseal joints, two at each level posteriorly which join the vertebrae together.
- Anteriorly the intervertebral disc serves as a cushion between the vertebrae but also helps join the vertebrae together and provides stability.
- Chronic low back pain is due t intervertebral disc disease in forty percent of patients, zygapophyseal joint dysfunction is fifteen to thirty percent of patients, sacro-iliac joint complex dysfunction in fifteen percent of patients, and in the remaining fifteen percent, multiple causes.
- the disc tissue becomes acidic and a degenerative process usually ensues. If the normal reparative process is inadequate, the disc can continue to degenerate and be the source of pain.
- the degenerative process varies in extent in every intervertebral disc that is chronically painful. A chemical reaction occurs within the disc usually at the site of injury. The chemicals cause further breakdown of the disc and when the chemicals escape into the spinal canal inflammation occurs and effects the spinal nerves causing further pain. In older patients (35 years plus) where degeneration is present the pain is not only due to a chemical reaction within the disc but instability of the disc secondary to previous degeneration.
- an intervertebral disc When an intervertebral disc can be identified as a source of pain usually by combination of a MRI scan of the lumbar spine as well as lumbar discography, the latter is a provocative test for discogenic pain by placing a needle into the center of the disc and injection of radiographic contrast under pressure. In a normal disc there is no pain provoked. In an abnormal disc pain is provoked, and if it causes the pain that is experienced by the patient, then the disc is concordantly painful.
- a buffer solution has also been added to the solution, namely a combination of mono and diphosphates which increases the pH level to above about 6.0, and preferably between about 6.3 to about 6.8 which is slightly acidic but within physiologic range.
- DMSO can be added to facilitate dispersion of the solution.
- DMSO serves essentially as a solvent.
- Chondroitin sulfate and glucosamine hydrochloride are substrates of collagen.
- Collagen is the basic building block of fibrous tissue, which the annular portion of the disc is comprised.
- the hypertonic dextrose stimulates growth factor as well as, it is believed, nourishes the chondrocytes and fibrocytes present within the intervertebral disc, and to some degree serves as a neurolytic agent for unmyelinated sensory nerve fibers that can penetrate the intervertebral disc.
- the disc restorative solution will mitigate the chemical-inflammatory condition within the disc and will stimulate gradually a reparative response, which will reduce pain and stabilize degenerative discs.
- the ingredients are formulated into pharmaceutically acceptable and tolerable carrier such as sterile water or normal saline in accordance with standard pharmaceutical practice. These ingredients are provided in a stock solution, which is then diluted or augmented to the desired concentrations and composition. The formulation is passed through a 2 micron filter.
- DMSO dimethyl sulfoxide
- the ingredients are formulated into a pharmaceutically-acceptable and tolerable carrier such as sterile water in accordance with good pharmaceutical practice. These ingredients are provided in a stock solution, which is then diluted or augmented to the desired concentrations and composition.
- a pharmaceutically-acceptable and tolerable carrier such as sterile water
- Improved injectables can be provided by the addition of other substances.
- sodiumcarboxymethylcellulose or a temporary anaesthetic such as Bupivicane can optionally be added to the stock solution in a respective amount of one percent each. This provides a modified stock solution, subject to the same later dilution.
- the stock solution (basic or modified) is conveniently made in 2 cc increments subject to later dilution.
- the sodium carboxymethylcellulose and anaesthetic when used are added to the basic stock solution, to form the 2 cc increment. In both events, 2 cc of water will be added to make the injectable.
- Two other optional ingredients can provide additional benefits. They are used as, or part of the diluent, each as 1 cc in place of 1 cc of dilution water.
- dextrose 50% solution. When added alone, it will be accompanied by 1 cc of dilution water. Then, when combined with the stock solution, it will be about 12.5% of the injectable.
- a contrast medium with or without an antibiotic of 2 cc can be provided. If only this ingredient is added, it will be accompanied by 1 cc of dilution water. These are provided in suitable physiological amounts.
- the presently preferred injectable is formulated as follows: Glucosamine 4% Chondroitin 0.75% Bupivicaine 0.5%
- the ratio or glucosamine to chondroitin can vary from about 3:1 to about 10:1.
- the presently preferred ratio is about 5 1/3:1.
- a stock solution can be prepared as follows, the components being given by weight percentages: Chondroitin Sulfate about 0.5% to about 2% Glucosamine HCl about 5.0% to about 20% Bupivicaine (optional) about 2.0% to about 4% Buffer substances in quantity sufficient to bring the pH above about 6.0. Sodium mono and di-phosphate are useful. Sterile Water to make 100%
- the preferred stock solution is as follows: Chondroitin Sulfate about 1.5% Glucosamine HCl about 8.0% Buffer substances in quantity sufficient to bring the pH above about 6.0. Sodium mono and di-phosphate are useful Sterile water to make 100%.
- This stock solution will provide a useful injectable when suitable diluted with sterile water.
- Chondroitin sulfate is an acidic irritant. Control over the pH of the injectable appears to alleviate some of its irritating effects. Accordingly it has been found that a pH close to neutral, but a bit on the acid side is better tolerated. Experiment has shown that a pH above about 6.0, is useful, preferably about 6.5 to 7.4. A buffer of monobasic sodium phosphate and dibasic phosphate in sterile water functions well for this purpose and is agreeable to the tissues. The actual amount will be determined by observing the pH value of the injectable when the solution is being prepared.
- the amount to be injected is for the discretion and judgement of the surgeon. His experience, and the “feel” of the syringe will be the best guidance. Several ccs of the injectable will be the usual dosage per disc.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An injectable for injection into a spinal disc, and a method to treat a spinal disc with the injectable. The injectable consists essentially of chondroitin sulfate and glucosamine HCl buffered to a pH above about 6.0.
Description
- This application is a continuation-in-part of applicant's co-pending U.S. patent application Ser. No. 10/441,130, filed Oct. 4, 2002, which will be abandoned after the filing of this continuation-in-part. In turn Ser No. 10/441,130 is a continuation-in-part of applicant's then co-pending application Ser No. 09/704,267, filed Oct. 31, 2000 (now abandoned).
- An injectable for, and a method of use to treat spinal discs.
- The human skeleton has evolved to allow for upright posture and bipedal motion. The human spine in its development to support the upright body has developed areas of stress particularly at the base of the neck, the apex of the mid back (thoracic spine) and in the lower back (lower lumbar spine). The spine is formed by bony elements, the vertebrae, and cushions between vertebrae, the intervertebral discs. The spine is then supported by ligaments, fibrous bands of tissue that join bones together, and muscles and fascia, which provide dynamic support and zygapophyseal joints, two at each level posteriorly which join the vertebrae together. Anteriorly the intervertebral disc serves as a cushion between the vertebrae but also helps join the vertebrae together and provides stability.
- When neck or back pain become chronic, usually due to injury or repetitive stress, and the pain becomes severe and limiting or disabling the intervertebral disc(s) is/are the source of pain.
- The most common cause of disability below the age of forty-five is chronic low back pain. Chronic low back pain is due t intervertebral disc disease in forty percent of patients, zygapophyseal joint dysfunction is fifteen to thirty percent of patients, sacro-iliac joint complex dysfunction in fifteen percent of patients, and in the remaining fifteen percent, multiple causes.
- When an intervertebral disc becomes injured, the natural reparative process is often hindered due to limited blood supply to the inner portion of the intervertebral disc. Normally blood vessels are found only in the outer third of the peripheral portion of the disc, the annulus. However nutrition to the central portion of the disc depends upon perfusion of nutrients through the vertebral end-plate which separates the disc from the body of the vertebra above and below.
- When nutrition becomes impaired the disc tissue becomes acidic and a degenerative process usually ensues. If the normal reparative process is inadequate, the disc can continue to degenerate and be the source of pain. The degenerative process varies in extent in every intervertebral disc that is chronically painful. A chemical reaction occurs within the disc usually at the site of injury. The chemicals cause further breakdown of the disc and when the chemicals escape into the spinal canal inflammation occurs and effects the spinal nerves causing further pain. In older patients (35 years plus) where degeneration is present the pain is not only due to a chemical reaction within the disc but instability of the disc secondary to previous degeneration.
- Low back pain is reaching epidemic proportions in the Western world. Traditionally the treatment for severe discogenic pain has been surgical removal of the injured intervertebral disc and fusion of the spine surgically by replacing the disc with bone graft or various metal implants containing bone graft. This procedure is very expensive. Costs can range up to one hundred thousand dollars. It requires from six months to one year to recover. Up to eighty percent of the fusions becomes solid. However pain improvement is problematical. At best fifty to sixty percent of patients experience pain reduction, not always completely. Up to fifty percent remain with the same degree of pain or worse. The latter group often becomes permanently disabled and dependent upon opioid medications.
- Upon evaluation of back pain many factors must be considered: age, severity of pain, radiation of pain into buttock or legs, and the presence of leg numbness or weakness. Commonly most patients who suffer an initial injury can recover fully if they rest appropriately, and inflammation within or about the disc is addressed. Thereafter a conditioning program becomes important in order to strengthen the muscles for supporting the trunk and providing controlled movement. When there is recurrence of low back pain after injury or stress the condition usually becomes more serious.
- When an intervertebral disc can be identified as a source of pain usually by combination of a MRI scan of the lumbar spine as well as lumbar discography, the latter is a provocative test for discogenic pain by placing a needle into the center of the disc and injection of radiographic contrast under pressure. In a normal disc there is no pain provoked. In an abnormal disc pain is provoked, and if it causes the pain that is experienced by the patient, then the disc is concordantly painful.
- At the same time fissures to the outer portion of the disc, the annulus, or multiple tears radiating from the center of the disc, the nucleus, to the periphery of the disc through the annulus are visualized. If the intervertebral disc has normal height, and there is a single fissure, and there is severe pain on low pressure by discogram, then a highly chemically sensitive disc is present. This condition is called an internal disc disruption. If multiple tears are identified, the disc has become narrowed by degeneration, and the pain is less severe but still significant, the condition is often called symptomatic degenerative disc disease.
- The traditional-treatment to the present time for severe painful discogenic disease has been spinal fusion. Successful results are modest. Therefore it is essential to find simpler and better ways to treat painful intervertebral discs. Several devices have been developed in recent years. At present there are two devices that are used relatively commonly, the first is the IDET (intra-discal electrothermal therapy) and the other is the nucleoplasty.
- These two devices have limited use. They can only be used on intervertebral discs that have nearly normal height, have a single fissure and are chemically sensitive. The nucleoplasty is also used when there is posterior bulging of the disc for it will remove or ease the central pressures within the disc and therefore the pressure upon the periphery of the disc is reduced. Their success is partial. No alternative treatment for internal disc disruption or symptomatic degenerative disc disease has been developed until the chemical disc injection treatment (disc restorative solution) of this invention.
- Observation based upon injection treatment of soft tissue injuries, namely ligaments, tendons and fascia, wherein the injected solution causes a mild inflammatory reaction followed by a reparative response within the tissues, led to the concept that painful and damaged intervertebral discs could be treated similarly. The solution selected to test this hypothesis was the combination of chondroitin sulfate, glucosamine HCl, hypertonic dextrose, bupivicaine and DMSO (dimethyl sulfoxide) when indicated. Because the solution becomes acidic with a pH of 4.3, a buffer solution has also been added to the solution, namely a combination of mono and diphosphates which increases the pH level to above about 6.0, and preferably between about 6.3 to about 6.8 which is slightly acidic but within physiologic range. In some conditions where the annular portion of the intervertebral disc has degenerated significantly and there appears to be inflamed areas within parts of the annulus, then DMSO can be added to facilitate dispersion of the solution. DMSO serves essentially as a solvent.
- Chondroitin sulfate and glucosamine hydrochloride are substrates of collagen. Collagen is the basic building block of fibrous tissue, which the annular portion of the disc is comprised.
- The hypertonic dextrose stimulates growth factor as well as, it is believed, nourishes the chondrocytes and fibrocytes present within the intervertebral disc, and to some degree serves as a neurolytic agent for unmyelinated sensory nerve fibers that can penetrate the intervertebral disc.
- In a recent study done by Klein, Eek et al (manuscript submitted for publication) presented a potential new alternative treatment for chronic disogenic back pain. Thirty patients were included in the study. All of the patients treated had positive discography at one or more levels as evidenced by concordant pain and morphologic disc disruption. The discs were injected with the disc solution as described. Three to four treatments were done at two to three month intervals. The patients were followed for approximately twelve months after completion of treatment. Seventeen patients improved on average seventy-four percent using the Roland-Morris functional questionnaire and the VAS pain scale. Thirteen patients did not improve significantly. These patients fell into varying groups, namely, failed posterior spinal fusion, spinal stenosis, generalized fibromyalgia syndrome, failed IDET procedure etc. Since that time over one hundred patients have been treated. Now the majority of patients are gradually improving. It requires up to a year to gain maximum improvement.
- It is believed that the disc restorative solution will mitigate the chemical-inflammatory condition within the disc and will stimulate gradually a reparative response, which will reduce pain and stabilize degenerative discs.
- The ingredients are formulated into pharmaceutically acceptable and tolerable carrier such as sterile water or normal saline in accordance with standard pharmaceutical practice. These ingredients are provided in a stock solution, which is then diluted or augmented to the desired concentrations and composition. The formulation is passed through a 2 micron filter.
- Common to all formulations according to this invention is the inclusion, in an injectable tolerated by the spinal disc, of both glucosamine and chondroitin sulfate (in a buffered injectable solution). Injections with only one of these constituents have proved to be without value, but their combination in a properly buffered solution has proved to be otherwise.
- The dispersion of this solution in the disc appears to be markedly improved by the optional inclusion of dimethyl sulfoxide (DMSO), which is an optional ingredient, but one which appears to provide for greater acceptance in the disc.
- Improved stability of the disc and reduction of pain appears to be provided by the incorporation of low viscosity sodiumcarboxymethylcellulose, which is also believed to coat sensory unmyelinated nerves in the discs.
- Important improvements to the comfort of the patient can be attained in all situations by the further inclusion of a local temporary-acting anaesthetic such as Marcaine (bupivicaine). Any lessening of pain, even during the brief period during and following the injection, can provide important benefits to an apprehensive patient, and reduce the inflammation caused by the insult of the needle and the event of the injection.
- The ingredients are formulated into a pharmaceutically-acceptable and tolerable carrier such as sterile water in accordance with good pharmaceutical practice. These ingredients are provided in a stock solution, which is then diluted or augmented to the desired concentrations and composition.
- For example, if only the ingredients in this stock solution are desired, an equal volume of water will be added to it, to reduce the concentration by half, thereby providing the injectable. The ratios between the ingredients will not be changed, but their concentration in the injectable will be reduced from what they were in the stock solution.
- Improved injectables can be provided by the addition of other substances.
- For example, either sodiumcarboxymethylcellulose or a temporary anaesthetic such as Bupivicane can optionally be added to the stock solution in a respective amount of one percent each. This provides a modified stock solution, subject to the same later dilution.
- The stock solution (basic or modified) is conveniently made in 2 cc increments subject to later dilution. The sodium carboxymethylcellulose and anaesthetic when used are added to the basic stock solution, to form the 2 cc increment. In both events, 2 cc of water will be added to make the injectable.
- Two other optional ingredients can provide additional benefits. They are used as, or part of the diluent, each as 1 cc in place of 1 cc of dilution water.
- One such ingredient is dextrose, 50% solution. When added alone, it will be accompanied by 1 cc of dilution water. Then, when combined with the stock solution, it will be about 12.5% of the injectable.
- Similarly, a contrast medium with or without an antibiotic of 2 cc can be provided. If only this ingredient is added, it will be accompanied by 1 cc of dilution water. These are provided in suitable physiological amounts.
- When both are used, they will replace the dilution water entirely.
- The presently preferred injectable is formulated as follows:
Glucosamine 4% Chondroitin 0.75% Bupivicaine 0.5% -
- Phosphate buffers to about 6.0, preferably about 6.7
- The above to make 50% by volume of this injectable, plus 12.5% by volume dextrose, plus 12.5% by volume of a solution of an aqueous solution and or antibiotic.
- In suitable-injectables, the ratio or glucosamine to chondroitin can vary from about 3:1 to about 10:1. The presently preferred ratio is about 5 1/3:1.
- A stock solution can be prepared as follows, the components being given by weight percentages:
Chondroitin Sulfate about 0.5% to about 2% Glucosamine HCl about 5.0% to about 20% Bupivicaine (optional) about 2.0% to about 4% Buffer substances in quantity sufficient to bring the pH above about 6.0. Sodium mono and di-phosphate are useful. Sterile Water to make 100% - The preferred stock solution is as follows:
Chondroitin Sulfate about 1.5% Glucosamine HCl about 8.0% Buffer substances in quantity sufficient to bring the pH above about 6.0. Sodium mono and di-phosphate are useful Sterile water to make 100%. - This stock solution will provide a useful injectable when suitable diluted with sterile water.
- Chondroitin sulfate is an acidic irritant. Control over the pH of the injectable appears to alleviate some of its irritating effects. Accordingly it has been found that a pH close to neutral, but a bit on the acid side is better tolerated. Experiment has shown that a pH above about 6.0, is useful, preferably about 6.5 to 7.4. A buffer of monobasic sodium phosphate and dibasic phosphate in sterile water functions well for this purpose and is agreeable to the tissues. The actual amount will be determined by observing the pH value of the injectable when the solution is being prepared.
- The amount to be injected is for the discretion and judgement of the surgeon. His experience, and the “feel” of the syringe will be the best guidance. Several ccs of the injectable will be the usual dosage per disc.
- This invention is not to be limited by the embodiments described in the description, which are given by way of example and not of limitation, but only in accordance with the scope of the appended claims.
Claims (13)
1. For injection directly into a disrupted spinal disc to reduce pain caused by the disrupted disc, an injectable consisting essentially of:
(a) a stock solution consisting by weight percentages, chondroitin sulfate, between about 0.5% to about 2.0% glucosamine HCl, between about 5.0% to about 20.0%, and sterile water to make 100%, and buffer substance in quantity sufficient to bring the pH of this injectable to a value above 6.0; and
(b) water to dilute said stock solution to a concentration tolerated by the disc.
2. An injectable according to claim 1 in which said stock solution further includes a solution of dextrose (about 50% by weight of its own solution) in the ratio between about 1:1 to about 3:2 by weight (dextrose: stock solution before adding dextrose solution).
3. An injectable according to claim 1 in which said stock solution further includes a temporary anesthetic.
4. An injectable according to claim 1 in which said stock solution further includes low viscosity sodium carboxymethylcellulose in concentration between about 0.5% to about 2.0%
5. An injectable according to claim 1 in which the concentration of chondroitin sulfate in the stock solution is between about 1.5%, and the concentration of glucosamine HCl about 8%.
6. An injectable according to claim 1 in which the ration of glucosamine to chondroitin is between about 3:1 to 10:1.
7. For injection directly into a disrupted spinal disc to reduce pain caused by the disrupted disc, a stock solution consisting essentially of: glucosamine HCl, about 8%, chondroitin sulfate about 1.5%, phosphate buffer substances to above pH 6.0, sterile water to make 100%; and
sterile water or normal saline solution to dilute the stock solution about by half.
8. An injectable according to claim 7 in which said stock solution for this includes low viscosity sodiumcarboxymethylcellulose, about 1.0%, and a temporary anaesthetic, about 1%.
9. An injectable according to claim 8 in which said stock solution further includes a volume of 50% dextrose, about ½ of the volume of the stock solution of claim 7 .
10. An injectable according to claim 9 in which said stock solution further includes a volume of contrast material and antibiotic about ½ of the volume of the stock solution of claim 7 .
11. The method of treating a disrupted spinal disc comprising injecting a physiologically acceptably amount of said injectable of claim 1 into said disc.
12. The method of treating a disrupted spinal disc comprising injecting the injectable of claim 7 into said disc.
13. The method of treating a disrupted spinal disc comprising injecting the injectable of claim 10 into said disc.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/210,307 US20050282774A1 (en) | 2000-10-31 | 2005-08-24 | Method and pharmaceutical to treat spinal discs |
US12/643,807 US8048865B2 (en) | 2000-10-31 | 2009-12-21 | Method and pharmaceutical to treat spinal discs |
US13/217,532 US20110312913A1 (en) | 2000-10-31 | 2011-08-25 | Method and pharmaceutical to treat spinal discs |
US13/426,531 US20120295867A1 (en) | 2000-10-31 | 2012-03-21 | Method and pharmaceutical to treat spinal discs |
US13/779,541 US20140066389A1 (en) | 2000-10-31 | 2013-02-27 | Method and pharmaceutical to treat spinal discs |
US14/656,566 US20170151276A9 (en) | 2000-10-31 | 2015-03-12 | Method and pharmaceutical to treat spinal discs |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70426700A | 2000-10-31 | 2000-10-31 | |
US10/441,130 US20030229049A1 (en) | 2000-10-31 | 2002-10-04 | Method and pharmaceutical to treat spinal discs |
US11/210,307 US20050282774A1 (en) | 2000-10-31 | 2005-08-24 | Method and pharmaceutical to treat spinal discs |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/441,130 Continuation-In-Part US20030229049A1 (en) | 2000-10-31 | 2002-10-04 | Method and pharmaceutical to treat spinal discs |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/643,807 Continuation US8048865B2 (en) | 2000-10-31 | 2009-12-21 | Method and pharmaceutical to treat spinal discs |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050282774A1 true US20050282774A1 (en) | 2005-12-22 |
Family
ID=46304972
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/210,307 Abandoned US20050282774A1 (en) | 2000-10-31 | 2005-08-24 | Method and pharmaceutical to treat spinal discs |
US12/643,807 Expired - Fee Related US8048865B2 (en) | 2000-10-31 | 2009-12-21 | Method and pharmaceutical to treat spinal discs |
US13/217,532 Abandoned US20110312913A1 (en) | 2000-10-31 | 2011-08-25 | Method and pharmaceutical to treat spinal discs |
US13/426,531 Abandoned US20120295867A1 (en) | 2000-10-31 | 2012-03-21 | Method and pharmaceutical to treat spinal discs |
US13/779,541 Abandoned US20140066389A1 (en) | 2000-10-31 | 2013-02-27 | Method and pharmaceutical to treat spinal discs |
US14/656,566 Abandoned US20170151276A9 (en) | 2000-10-31 | 2015-03-12 | Method and pharmaceutical to treat spinal discs |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/643,807 Expired - Fee Related US8048865B2 (en) | 2000-10-31 | 2009-12-21 | Method and pharmaceutical to treat spinal discs |
US13/217,532 Abandoned US20110312913A1 (en) | 2000-10-31 | 2011-08-25 | Method and pharmaceutical to treat spinal discs |
US13/426,531 Abandoned US20120295867A1 (en) | 2000-10-31 | 2012-03-21 | Method and pharmaceutical to treat spinal discs |
US13/779,541 Abandoned US20140066389A1 (en) | 2000-10-31 | 2013-02-27 | Method and pharmaceutical to treat spinal discs |
US14/656,566 Abandoned US20170151276A9 (en) | 2000-10-31 | 2015-03-12 | Method and pharmaceutical to treat spinal discs |
Country Status (1)
Country | Link |
---|---|
US (6) | US20050282774A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070253928A1 (en) * | 2006-04-28 | 2007-11-01 | Josee Roy | Pharmaceutical removal of neuronal extensions from a degenerating disc |
US20070253930A1 (en) * | 2006-04-28 | 2007-11-01 | Josee Roy | Pharmaceutical removal of vascular and/or neuronal extensions form a degenerating disc |
US20070253960A1 (en) * | 2006-04-28 | 2007-11-01 | Josee Roy | Pharmaceutical removal of vascular extensions from a degenerating disc |
US11318187B1 (en) * | 2021-09-02 | 2022-05-03 | Bjorn Eek | Treatment of internal disc disruption and connective tissue injuries |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010101620A2 (en) | 2009-03-02 | 2010-09-10 | Seventh Sense Biosystems, Inc. | Systems and methods for creating and using suction blisters or other pooled regions of fluid within the skin |
US9041541B2 (en) * | 2010-01-28 | 2015-05-26 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
US9295417B2 (en) | 2011-04-29 | 2016-03-29 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
US20110172510A1 (en) * | 2010-01-13 | 2011-07-14 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or withdrawal of fluids |
US9033898B2 (en) * | 2010-06-23 | 2015-05-19 | Seventh Sense Biosystems, Inc. | Sampling devices and methods involving relatively little pain |
EP2493535A2 (en) * | 2009-10-30 | 2012-09-05 | Seventh Sense Biosystems, Inc. | Systems and methods for application to skin and control of actuation, delivery and/or perception thereof |
EP2493537B1 (en) * | 2009-10-30 | 2017-12-06 | Seventh Sense Biosystems, Inc. | Systems and methods for treating, sanitizing, and/or shielding the skin or devices applied to the skin |
WO2011065972A2 (en) * | 2009-11-24 | 2011-06-03 | Seventh Sense Biosystems, Inc. | Patient-enacted sampling technique |
CN102791197B (en) * | 2010-01-13 | 2016-03-23 | 第七感生物系统有限公司 | Sampler interface |
EP2593014B1 (en) | 2010-07-16 | 2015-11-04 | Seventh Sense Biosystems, Inc. | Low-pressure environment for fluid transfer devices |
US20130158482A1 (en) | 2010-07-26 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
US20120039809A1 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
EP2637562B1 (en) | 2010-11-09 | 2016-01-27 | Seventh Sense Biosystems, Inc. | Systems and interfaces for blood sampling |
US8398611B2 (en) | 2010-12-28 | 2013-03-19 | Depuy Mitek, Inc. | Compositions and methods for treating joints |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
EP2702406B1 (en) | 2011-04-29 | 2017-06-21 | Seventh Sense Biosystems, Inc. | Plasma or serum production and removal of fluids under reduced pressure |
ES2597081T3 (en) | 2011-04-29 | 2017-01-13 | Seventh Sense Biosystems, Inc. | Delivery and / or reception of fluids |
US9682099B2 (en) * | 2015-01-20 | 2017-06-20 | DePuy Synthes Products, Inc. | Compositions and methods for treating joints |
NZ759326A (en) * | 2015-11-06 | 2022-10-28 | Univ Health Network | Compositions and methods for degenerative disc regeneration |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046187A (en) * | 1996-09-16 | 2000-04-04 | Children's Medical Center Corporation | Formulations and methods for providing prolonged local anesthesia |
US6476005B1 (en) * | 1998-03-24 | 2002-11-05 | George D. Petito | Oral and injectable nutritional composition |
US6562873B2 (en) * | 2000-07-14 | 2003-05-13 | Allergan, Inc. | Compositions containing therapeutically active components having enhanced solubility |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5211937A (en) | 1990-07-30 | 1993-05-18 | Glycomed Incorporated | Method of determining a site of inflammation utilizing elam-1 ligands |
US6063405A (en) | 1995-09-29 | 2000-05-16 | L.A.M. Pharmaceuticals, Llc | Sustained release delivery system |
US6255295B1 (en) | 1996-12-23 | 2001-07-03 | Nutramax Laboratories, Inc. | Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue |
-
2005
- 2005-08-24 US US11/210,307 patent/US20050282774A1/en not_active Abandoned
-
2009
- 2009-12-21 US US12/643,807 patent/US8048865B2/en not_active Expired - Fee Related
-
2011
- 2011-08-25 US US13/217,532 patent/US20110312913A1/en not_active Abandoned
-
2012
- 2012-03-21 US US13/426,531 patent/US20120295867A1/en not_active Abandoned
-
2013
- 2013-02-27 US US13/779,541 patent/US20140066389A1/en not_active Abandoned
-
2015
- 2015-03-12 US US14/656,566 patent/US20170151276A9/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046187A (en) * | 1996-09-16 | 2000-04-04 | Children's Medical Center Corporation | Formulations and methods for providing prolonged local anesthesia |
US6476005B1 (en) * | 1998-03-24 | 2002-11-05 | George D. Petito | Oral and injectable nutritional composition |
US6562873B2 (en) * | 2000-07-14 | 2003-05-13 | Allergan, Inc. | Compositions containing therapeutically active components having enhanced solubility |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070253928A1 (en) * | 2006-04-28 | 2007-11-01 | Josee Roy | Pharmaceutical removal of neuronal extensions from a degenerating disc |
US20070253930A1 (en) * | 2006-04-28 | 2007-11-01 | Josee Roy | Pharmaceutical removal of vascular and/or neuronal extensions form a degenerating disc |
US20070253960A1 (en) * | 2006-04-28 | 2007-11-01 | Josee Roy | Pharmaceutical removal of vascular extensions from a degenerating disc |
US8916611B2 (en) | 2006-04-28 | 2014-12-23 | Warsaw Orthopedic, Inc. | Pharmaceutical removal of neuronal extensions from a degenerating disc |
US9730986B2 (en) | 2006-04-28 | 2017-08-15 | Warsaw Orthopedic, Inc. | Pharmaceutical removal of neuronal extensions from a degenerating disc |
US9789161B2 (en) | 2006-04-28 | 2017-10-17 | Warsaw Orthopedic, Inc. | Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin |
US10517930B2 (en) | 2006-04-28 | 2019-12-31 | Warsaw Orthopedic, Inc. | Methods for treating back or neck pain caused by NGF using a therapeutic agent comprising REN-1820, ALE-0540 and capsaicin |
US11318187B1 (en) * | 2021-09-02 | 2022-05-03 | Bjorn Eek | Treatment of internal disc disruption and connective tissue injuries |
Also Published As
Publication number | Publication date |
---|---|
US20120295867A1 (en) | 2012-11-22 |
US20110312913A1 (en) | 2011-12-22 |
US8048865B2 (en) | 2011-11-01 |
US20170151276A9 (en) | 2017-06-01 |
US20110003770A1 (en) | 2011-01-06 |
US20160310520A1 (en) | 2016-10-27 |
US20140066389A1 (en) | 2014-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8048865B2 (en) | Method and pharmaceutical to treat spinal discs | |
Murakami et al. | Effect of periarticular and intraarticular lidocaine injections for sacroiliac joint pain: prospective comparative study | |
Przybylski et al. | Single-stage autogenous bone grafting and internal fixation in the surgical management of pyogenic discitis and vertebral osteomyelitis | |
Mielke et al. | Surgical treatment of adolescent idiopathic scoliosis. A comparative analysis. | |
Blume | Unilateral posterior lumbar interbody fusion: simplified dowel technique. | |
Li et al. | Anterior discectomy/corpectomy and fusion with internal fixation for the treatment of unstable hangman's fractures: a retrospective study of 38 cases | |
van Ooij et al. | Surgical treatment of aspergillus spondylodiscitis | |
Karaeminogullari et al. | Tuberculosis of the lumbar spine: outcomes after combined treatment of two-drug therapy and surgery | |
Mukhtar et al. | Surgical treatment of thoracic and lumbar tuberculosis by anterior interbody fusion and posterior instrumentation | |
Sutro | Effects of subcutaneous injection of estrogen upon skeleton in immature mice | |
US20030229049A1 (en) | Method and pharmaceutical to treat spinal discs | |
Kim et al. | Nerve-root injections for the relief of pain in patients with osteoporotic vertebral fractures | |
US20140057973A1 (en) | Pharmaceutical composition for treating and preventing diseases related to joint and connective tissue | |
RU2268052C2 (en) | Agent for treatment of inflammatory and degenerative joint disease (variants), method for treatment of inflammatory and degenerative joint disease (variants) and device for delivery of medicinal agent to damaged site | |
Harris JR | Glucocorticoid use in rheumatoid arthritis | |
Kandel et al. | Minimal invasive dynamic hip screw fixation for intertrochanteric fractures of femur | |
Kurosawa et al. | Three-year clinical outcomes after minimally invasive sacroiliac joint arthrodesis using triangular implants in Japan: a pilot study of five cases | |
Sgouros | Surgical management of spasticity of cerebral origin in children | |
KARADUMAN et al. | A Comparison of the Modified Bosworth and Endobutton Techniques in the Surgical Treatment of Rockwood Type III Acromioclavicular Joint Dislocations | |
Zhu et al. | Hip abductor tendon tears-a survey of New Zealand orthopaedic surgeons. | |
Joshi et al. | Outcomes of osteosynthesis versus hemiarthroplasty in elderly patients with arbeitsgemeinschaft fur osteosynthesefragen-orthopedic trauma association (AO-OTA) 31A2 hip fractures | |
Funahashi et al. | Long-term oral meclozine administration improves survival rate and spinal canal stenosis during postnatal growth in a mouse model of achondroplasia in both sexes | |
Assid et al. | Long-Term Outcomes of Osteochondral Allograft with Osteogenic Protein-1 Augmentation: A Twelve-Year Follow-Up | |
Karaeminogullari et al. | Tuberculosis of the lumbar spine: outcomes after combined treatment with short-course two-drug therapy and surgery | |
Mirghaderi et al. | Severely Comminuted Transolecranon Fracture Fixation with the Help of Medial Humerus Anatomical Plate: A Case Report and Educational Corner |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NOTOGEN, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EEK, BJORN C. J.;REEL/FRAME:041056/0080 Effective date: 20170113 |